USS Investment Management Ltd Acquires 188,917 Shares of Medtronic PLC $MDT

USS Investment Management Ltd increased its holdings in shares of Medtronic PLC (NYSE:MDT – Free Report) by 7.4% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 2,737,475 shares of the medical technology company’s stock after buying an additional 188,917 shares during the quarter. Medtronic comprises approximately 0.9% of USS Investment Management Ltd’s portfolio, making the stock its 18th biggest holding. USS Investment Management Ltd owned approximately 0.21% of Medtronic worth $236,162,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in MDT. BlackRock Inc. grew its holdings in Medtronic by 0.7% in the 2nd quarter. BlackRock Inc. now owns 114,020,787 shares of the medical technology company’s stock valued at $8,919,846,000 after buying an additional 838,220 shares during the period. State Street Corp increased its stake in shares of Medtronic by 2.7% during the 2nd quarter. State Street Corp now owns 63,399,315 shares of the medical technology company’s stock valued at $5,005,320,000 after acquiring an additional 1,658,301 shares during the last quarter. Bank of America Corp DE increased its stake in shares of Medtronic by 5.4% during the 1st quarter. Bank of America Corp DE now owns 26,015,003 shares of the medical technology company’s stock valued at $2,254,200,000 after acquiring an additional 1,343,220 shares during the last quarter. First Eagle Investment Management LLC lifted its holdings in shares of Medtronic by 1.2% during the 3rd quarter. First Eagle Investment Management LLC now owns 13,948,408 shares of the medical technology company’s stock worth $1,203,608,000 after acquiring an additional 164,425 shares during the period. Finally, Amundi lifted its holdings in shares of Medtronic by 36.3% during the 1st quarter. Amundi now owns 6,070,236 shares of the medical technology company’s stock worth $525,986,000 after acquiring an additional 1,616,739 shares during the period. 82.06% of the stock is currently owned by hedge funds and other institutional investors.

Medtronic Stock Performance

Shares of NYSE:MDT opened at $100.57 on Friday. The business has a 50-day moving average of $94.44 and a two-hundred day moving average of $88.47. The firm has a market capitalization of $128.64 billion, a PE ratio of 24.77, a P/E/G ratio of 2.36 and a beta of 0.56. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.07 and a quick ratio of 1.54. Medtronic PLC has a 12 month low of $73.31 and a 12 month high of $106.33.

Medtronic (NYSE:MDT – Get Free Report) last released its quarterly earnings data on Tuesday, September 1st. The medical technology company reported $1.45 earnings per share for the quarter, beating the consensus estimate of $1.39 by $0.06. Medtronic had a return on equity of 14.78% and a net margin of 13.93%. The business had revenue of $9.76 billion for the quarter, compared to analyst estimates of $9.55 billion. During the same period in the previous year, the company posted $1.26 EPS. The company’s revenue was up 13.7% compared to the same quarter last year. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. As a group, research analysts forecast that Medtronic PLC will post 5.98 earnings per share for the current year.

Analysts Set New Price Targets

MDT has been the topic of several research analyst reports. Barclays raised shares of Medtronic to a “hold” rating in a research report on Wednesday, October 7th. Robert W. Baird upped their price target on shares of Medtronic from $91.00 to $100.00 and gave the stock a “neutral” rating in a research report on Wednesday, September 2nd. Piper Sandler raised shares of Medtronic from a “neutral” rating to an “overweight” rating and increased their price target for the stock from $85.00 to $120.00 in a research note on Tuesday. TD Cowen set a $110.00 price target on shares of Medtronic and gave the stock a “buy” rating in a research note on Tuesday. Finally, Bank of America lifted their price target on shares of Medtronic from $95.00 to $110.00 and gave the company a “buy” rating in a report on Wednesday, September 2nd. Eighteen equities research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $104.17.

View Our Latest Report on Medtronic

Recent Medtronic Headlines

Investors following MDT have been watching these headlines:

  • Positive Sentiment: BTIG Research raised its price target on Medtronic to $109 from $99 and reiterated a Buy rating, signaling confidence in further upside. BTIG Research rating and price target
  • Neutral Sentiment: A preview of Medtronic’s fiscal second-quarter results focused on expected metrics but did not report actual results, leaving investors awaiting the earnings update. Medtronic Q2 earnings preview
  • Negative Sentiment: The outlook discussion also flags margin and currency headwinds, which could limit the benefit of growth in Hugo, international markets and Neuroscience. Medtronic hold analysis

Insider Activity at Medtronic

In other Medtronic news, EVP Harry Kiil sold 1,483 shares of the business’s stock in a transaction that occurred on Wednesday, September 16th. The shares were sold at an average price of $93.65, for a total transaction of $138,882.95. Following the completion of the sale, the executive vice president directly owned 42,186 shares in the company, valued at $3,950,718.90. The trade was a 3.40% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Geoffrey Martha sold 50,000 shares of the business’s stock in a transaction that occurred on Thursday, October 15th. The stock was sold at an average price of $95.00, for a total transaction of $4,750,000.00. Following the sale, the chief executive officer owned 277,866 shares of the company’s stock, valued at approximately $26,397,270. This represents a 15.25% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 61,903 shares of company stock worth $5,889,203. Company insiders own 0.27% of the company’s stock.

Medtronic Company Profile

(Free Report)

Medtronic plc is a medical technology company that develops and manufactures devices and therapies for a range of health conditions. Its products include pacemakers and defibrillators, heart valves, surgical technologies, neurostimulation devices, and insulin pumps and other diabetes-management products. The company was founded in Minneapolis in 1949 by Earl Bakken and Palmer Hermundslie as a medical equipment repair business. It has since grown into a global company serving patients and health care providers in more than 150 countries.

Featured Articles

Want to see what other hedge funds are holding MDT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medtronic PLC (NYSE:MDT – Free Report).

Institutional Ownership by Quarter for Medtronic (NYSE:MDT)

Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.